India's Alkem Labs rises as Q1 results beat analysts' estimate

Alkem Laboratories

13/08/2025 05:35

** Alkem Laboratories ALKE.NS rises 3.4% to 5,326 rupees

** Drugmaker extends gains to second day after Q1 FY26 results on Tuesday

** Multiple brokerages highlight co's earnings beat across revenue, EBITDA, PAT

** Jefferies upgrades to "buy" from "underperform"

** Raises PT to 6,000 from 4,460 rupees, implying 16.5% upside from last close

** Macquarie maintains "underperform"; keeps PT at 4,500 rupees

** Says solid all-round beat driven by lower-than-expected other expenses

** HSBC retains "hold"; raises PT to 4,910 rupees from 4,825 rupees

** Likes long-term India portfolio outlook, but remains cautious on U.S. trends, spending on new initiatives

** YTD, ALKE falls 5.5%

 (Reporting by Rudra Pratap Singh in Bengaluru)

 ((rudrapratap.singh@thomsonreuters.com))